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Abstract 
Acute pulmonary embolism (APE) is one of the leading causes of cardiovascular (CV) 
morbidity and mortality. To select appropriate therapeutic strategy and/or to minimize the 
mortality and morbidity, rapid and correct identification of life-threatening APE is very 
important. Also, right ventricular (RV) failure usually precedes acute hemodynamic 
compromise or death, and thus the identification of RV failure is another important step in 
risk stratification or treatment of APE. With advances in diagnosis and treatment, the 
prognosis of APE has been dramatically improving in most cases, but inadequate therapy or 
recurrent episodes of pulmonary embolism (PE) may result in negative outcomes or, so called, 
chronic thromboembolic pulmonary hypertension (CTEPH). CTEPH is a condition with the 
remaining of chronic thromboembolism in the pulmonary vasculature which induces chronic 
pulmonary hypertension.  
Various imaging modalities include chest computed tomography pulmonary angiography 
(CTPA), echocardiography, magnetic resonance imaging, and nuclear imaging and each are 
used for the assessment of varying status of PE. Assessment of thromboembolic burden by 
chest CTPA is the first step in the diagnosis of PE. Hemodynamic assessment can be achieved 
by echocardiography and also by chest CTPA. Nuclear imaging is useful in discriminating  
CTEPH from APE. 
Better perspectives on diagnosis, risk stratification and decision making in PE can be 
provided by combining multimodality cardiovascular imaging. Here, the advantages or 
pitfalls of each imaging modality in diagnosis, risk stratification, or management of PE will 
be discussed.  
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Introduction 
 Acute pulmonary embolism (APE) refers to a condition in which the pulmonary 
vasculatures are abruptly occluded by abnormal thrombi or emboli, usually originating from 
deep veins of the lower extremities. Because APE may result in right ventricular (RV) 
dysfunction and hemodynamic compromise, APE is one of the major causes of mortality  
worldwide [1, 2]. The rapid and correct diagnosis of APE is essential in selecting an 
appropriate therapeutic strategy and to reduce mortality from APE. In this regard, multi-
modality cardiovascular (CV) imaging, including chest computed tomography (CT), 
computed tomography pulmonary angiography (CTPA) and echocardiography are useful not 
only in the diagnosis of APE, but also in the evaluation of hemodynamic significance of APE 
and thus clinical decision making and therapeutic strategy [3]. The evaluation of therapeutic 
efficacy is another important role of CV imaging in APE. 
 With the advances in diagnosis, treatment and prognosis of APE has been dramatically 
improved in most of cases. Inadequate therapy or recurrent episodes of pulmonary embolism 
(PE) may result in a serious negative outcomes, including so called chronic thromboembolic 
pulmonary hypertension (CTEPH). Although the pathogenesis of CTEPH is not completely 
understood, unresolved organized fibrotic thrombi or emboli, subsequent endothelial 
dysfunction and abnormal vascular remodeling seem to be involved in the development of 
pulmonary hypertension (PH). In case of CTEPH, RV can initially adapt to the increased 
afterload by PH through the process of RV dilatation and hypertrophy, but a progressive or 
sustained significant increase of pulmonary artery pressure results in RV failure and death [4]. 
Contrary to the evanescent role of nuclear imaging in APE, ventilation/perfusion (V/Q) scan 
is an imaging of choice in the detection of CTEPH [5].  
 In this review, the advantages and pitfalls of each imaging modality in diagnosis, risk 
stratification, and/or management of PE will be discussed. 
 
Role of TTE  
 Although transthoracic echocardiography (TTE) is the most widely used CV imaging 
modality in the assessment of cardiac function and structure, it plays a limited role in the 
diagnosis of APE because TTE cannot directly visualize the location or extent of pulmonary 
arterial thrombi or emboli in many cases. However, TTE has a critical role in evaluating 
hemodynamic significance of APE, including RV dysfunction, and thus TTE is the most 
useful CV imaging modality in risk stratification, clinical decision making of therapeutic 
strategy, or evaluating the prognosis of APE [6]. Furthermore, TTE can provide the first 
indications for diagnosing APE frequently, because it is the most widely used CV imaging 
modality in patients with dyspnea or chest pain. 
 The presence of RV dysfunction in APE is a hallmark of higher risk patients and an 
independent predictor of adverse clinical outcomes, and sometimes it can advocate 
emergency reperfusion treatment for APE. Therefore, the echocardiographic evaluation of RV 
function is an important step in the evaluation of APE [7]. Echocardiographic findings 
suggesting RV dysfunction include RV dilatation, hypokinesia or akinesia of the RV free wall 
and relative sparing of RV apical wall motion (Mc Connell’s sign), decreased tricuspid 
annulus plan systolic excursion (TAPSE) or fractional area change (FAC), and diminished 
RV longitudinal strain (Fig. 1) [8–13]. In addition, an increased RV systolic pressure assessed 
by measuring the peak velocity of tricuspid regurgitation (TR) jet or the increased size of the 
inferior vena cava or the change of an inferior vena cava size of less than 50% with 
inspiration can be a supportive sign of RV dysfunction [14]. Despite RV hypokinesia and 
pulmonary hypertension, RV hypertrophy is not a finding of APE because of the acute nature 
of the illness. Contrary to APE, RV hypertrophy with moderate to severe PH is a common 
finding in CTEPH as a consequence of adaptation of RV to an elevated afterload. Accordingly, 
RV hypertrophy on TTE is a simple qualitative clue for chronic PE [15]. 
 In summary, the role of TTE in PE can be summarized as follows; 1) TTE is an imaging 
of choice in the evaluation of hemodynamic significance including RV dysfunction and thus 
risk stratification or clinical decision making of therapeutic strategy of known APE; 2) TTE 
can provide the first indication for suspecting APE in some patients; 3) RV hypertrophy with 
PH in patients with known PE may suggest a finding of CTEPH. 
 
Chest CTPA 
 Rapid availability and reliability in diagnosis, has made chest CTPA the gold standard 
CV imaging for the evaluation of suspected APE, and actually it replaced the role of the V/Q 
scan in the diagnosis of APE. According to the PIOPED (Prospective Investigation of 
Pulmonary Embolism Diagnosis) II trial, CTPA appeared to have high negative predictive 
value (96%) in patients with low clinical probability for APE and also has a high positive 
predictive value (96%) in patients with high clinical probability for APE [16]. Hence, current 
guidelines recommend performing CTPA in patients highly suspected for APE or even in 
patients with low to intermediate clinical probability for APE when they have hypotension or 
shock. 
 Besides the role in diagnosing APE, chest CTPA can provide information about 
hemodynamic significance of APE. Previous studies have shown that RV enlargement of 
chest CTPA is a marker for RV dysfunction in patients with APE (Fig. 2A) [17, 18]. RV 
enlargement can be evaluated by measuring RV dimension to left ventricular dimension 
(RVD/LVD) ratio in a 4-chamber view of the chest CTPA, and RVD/LVD ratio greater than 
1.0 is suggested as a reliable marker for RV dysfunction in a meta-analysis [19]. RVD/LVD 
ratio greater than 0.9 on chest CTPA was used as a marker for RV dysfunction in another 
prospective cohort study [20]. In a previous study, the optimal cut-off value of RVD/LVD 
ratio on CTPA for predicting RV dysfunction was 1.12 [21]. Leftward ventricular septal 
bowing and contrast reflux to the inferior vena cava on CTPA are also considered as 
suggestive findings of RV dysfunction in APE (Fig. 2B–D), but the diagnostic sensitivity 
and/or specificity of these findings are lower than those of RVD/LVD ratio. For these reasons, 
the measurement of RVD/LVD ratio has proved to be the most reliable predictor of mortality 
in patients with APE among CTPA measurements [21–23]. 
 Chest CTPA also enables assessment of the presence, location, and degree of thrombi 
burden in APE (Fig. 3). Several scoring systems have been developed to evaluate the severity 
of a current episode of APE by measuring PA clot loads (Table 2) [24–28]. Qanadli index is a 
scoring system that evaluates the embolic burden by combining the total number of involved 
pulmonary vascular segments and degree of embolic obstruction [25]. Some studies 
demonstrated that the Qanadli index was a good predictor of RV dysfunction or mortality in 
APE, but it was not a predictor of RV dysfunction or mortality from APE in other studies 
[29–32]. Therefore, the clinical significance of these PA clot load scoring systems for the 
prediction of RV dysfunction or mortality in patients with APE should be clarified through 
further and larger studies. 
 With recent advances in processing of CT images, dual energy CT (DECT) has become 
available for the assessment of pulmonary parenchyma perfusion, by using iodine-subtraction 
techniques [33]. Perfusion defect or hypo-perfused region corresponding to the vascular 
obstruction is indicative of PE (Fig. 4). Thus, DECT can be useful in the assessment of PE 
without evidence of overt thrombus on CTPA. However, the diagnostic or prognostic role of 
DECT in APE remains poorly defined. Further research should be conducted to investigate 
the role of quantitative DECT on clinical outcomes in patients with APE. 
 Chest CTPA is an imaging of choice for the diagnosis of APE, but CTPA alone cannot 
exclude or confirm CTEPH completely. In the current guidelines, V/Q lung scan still remains 
the first-line imaging modality for the detection of CTEPH because V/Q scans demonstrate 
better sensitivity and specificity for the diagnosis of CTEPH as compared to those of chest 
CTPA [3, 34]. Nevertheless, several findings of chest CTPA can be useful in differentiating 
CTEPH from APE and CTEPH. The eccentric wall-adherent or mural thrombi, which are 
often calcified, is a relatively specific finding of CTEPH on CTPA (Fig. 5A, B). Complete 
vessel cutoff with convex margin due to organized thrombi is another specific feature of 
CTEPH, which is different from the concave margin of acute PE with a tapering of thrombus 
(Fig. 5C, D). An additional finding of CTEPH is the abrupt narrowing of the vessel distal to 
complete obstruction, due to contraction of the thrombus in chronic PE. Intraluminal webs or 
band and intimal irregularities by organized thrombi are not pathognomic but suggestive that 
findings with CTPA are consistent with CTEPH as well. In the chronic type of PE, 
development of collateral systemic circulation such as bronchial artery dilatation is frequently 
observed [35–37]. In addition, a non-uniform arterial perfusion pattern and mosaic pattern of 
lung attenuation can be observed on CTPA in CTEPH (Fig. 5E, F). When chest CTPA 
revealed these findings, the possibility of CTEPH should be carefully monitored even in 
patients who were first diagnosed as PE. 
 In summary, the role of chest CTPA in PE can be summarized as follows; 1) chest CTPA 
is a gold standard CV imaging for the evaluation of suspected APE, and it has replaced the 
role of V/Q scan in the diagnosis of APE; 2) chest CTPA is useful in the evaluation of RV 
dysfunction in APE and thus risk stratification or clinical decision making of therapeutic 
strategy, especially before performing TTE or when TTE is not available; 3) chest CTPA 
enables a quantitative assessment of PA clot loads by using a scoring system and DECT 
allows an assessment of pulmonary parenchyma perfusion, but the significance of these 
techniques should be validated through larger, future studies; 4) several findings of CTPA can 
be useful in differentiating CTEPH from APE, even though a V/Q scan is an imaging of 
choice in the diagnosis of CTEPH. 
 
Nuclear imaging: Ventilation/perfusion scintigraphy 
V/Q scan is an established diagnostic test for suspected PE. The main finding of V/Q scans 
in PE is that of perfusion (Q) defect without corresponding ventilation (V) defect, which is 
recognized as a V/Q mismatch (Fig. 6). Interpretation of the V/Q scan is important, 
considering the fact that there are other medical conditions that might cause a V/Q mismatch, 
such as veno-occlusive disorder, vasculitis, congenital pulmonary vascular abnormalities, 
pulmonary artery sarcoma, fibrosing mediastinitis, malignancy and mediastinal 
lymphadenopathy. Currently, the modified PIOPED II and prospective investigative study of 
acute pulmonary embolism diagnosis (PISAPED) criteria are most commonly used in the 
interpretation, with a sensitivity of 85% vs. 80% and specificity of 93% vs. 97%, respectively 
[38, 39]. 
These systems classify studies as high probability, very low probability, normal and non-
diagnostic. Current guideline recommends  excluding PE when the study has been classified 
as normal, and to confirm PE when the study has been classified as high probability [3]. 
Presently, the V/Q scan is one of the most useful imaging modalities in screening CTEPH 
in patients with PH in the absence or disappearance of PE. In CTEPH, V/Q scans reveal at 
least one segmental perfusion defect despite normal ventilation. According to the current 
guidelines, V/Q scan is recommended as a first-line imaging modality for CTEPH, with 96–
97% sensitivity and 90–95% specificity for diagnosis [3]. 
Recently, the introduction of single photon emission computed tomography (SPECT) into 
V/Q scintigraphy has emerged, which enables  defining the size and location of perfusion 
defects more accurately, using a 3-dimensional imaging technique [40]. Accordingly, the 
diagnostic performance of SPECT V/Q has been increasing with higher reproducibility and 
lower indeterminate rate compared to V/Q scanning [41–43]. 
In summary, the role of the V/Q scan can be summarized as follows; 1) V/Q scan has high 
diagnostic accuracy in the evaluation of PE; 2) V/Q scan is useful in the discrimination of 
CTEPH from APE, and is recommended as a first-line diagnostic tool for CTEPH. 
 
Magnetic resonance pulmonary angiography  
Magnetic resonance pulmonary angiography (MRPA) is another non-invasive imaging 
modality that can provide information about not only morphological assessment, but also 
functional assessment in patients with PE.  
With MRPA, vascular deformities such as vascular filling defects, complete absence of 
vessel enhancement, post-stenotic dilatation, and dilatation of a main pulmonary artery can be 
detected [44]. As with CTPA, irregular luminal filling defects, intraluminal webs and bands, 
vessel cutoffs and organized thrombi are indicative findings of CTEPH [45]. 
Recent research have shown that pulmonary artery flow can be assessed using phase 
contrast magnetic resonance [46]. Three- and four-dimensional phase contrast magnetic 
resonance imaging provides visualization of vortex flow changes in pulmonary arteries [46, 
47]. 
However, MRPA has lower sensitivity of PE compared to CTPA, especially in peripheral 
involvements [48]. The Main advantages of MRPA are that it is free of ionizing radiation and 
can provide information on structure and flow mechanics [49–51]. 
Nevertheless, MRPA is not recommended for routine investigation of PE, because of its 
limited availability, technically inadequate studies, reduced robustness and higher cost [3]. 
MRPA is anticipated as a promising imaging tool in the diagnosis of PE, however further 
studies are warranted for the clinical use of MRI in the diagnosis of PE. 
 
Role of conventional pulmonary angiography 
Pulmonary angiography provides direct visualization of obstructed vasculature or thrombi 
and also hemodynamic measurements [52]. It offers better visualization of peripheral 
pulmonary vessels, which can go undetected with other non-invasive imaging modalities, 
such as CTPA or MRPA. Filling defect or loss of pulmonary arterial branch is an indicative 
sign of PE. Currently, pulmonary angiography is more useful in patients suspected for 
CTEPH. Similar to CTPA findings, complete vessel cutoff with convex contour of thrombi, 
abrupt vessel narrowing, luminal irregularity and intravascular bands or webs are indicative 
signs of CTEPH rather than APE [36]. 
In patients with APE with shock or hypotension, prompt catheter-directed thrombolysis or 
thrombectomy can be performed after diagnosis of APE. Otherwise in patients with PH with 
suspected CTEPH, pulmonary balloon angioplasty followed by diagnostic pulmonary 
angiography can be performed for PH relief [3, 34, 53, 54]. 
 
Role of venous compression ultrasonography 
The role of lower extremity venous compression ultrasonography (CUS) in the routine 
diagnostic strategy is limited because of its low sensitivity for PE [3, 55]. 
With the advancements in technology, CTPA has shown better diagnostic performance in 
detecting PE compared to CUS [56]. However, it is useful to perform a CUS in diagnosing 
PE, in cases where it is difficult to obtain CTPA, such as pregnant women, patients with 
chronic kidney disease or with an allergy to contrast media [57, 58]. 
 
Imaging modalities in special cases  
Pregnancy 
The imaging modality of choice in the diagnosis of deep vein thrombosis (DVT) of the 
lower limb in pregnancy is CUS. Abnormal D-dimer and proximal DVT founded by lower 
extremity compressive venous sonography warrants anticoagulation therapy and makes 
thoracic imaging unnecessary. 
Guidelines recommend performing a V/Q scan over CTPA in the diagnosis of PE in 
pregnant women. The V/Q scan protocol can be adjusted to lower fetal and maternal radiation 
exposure. A low dose perfusion scan can be performed with a half dose of routine 
radiopharmaceutical agents. It is not fully established, but V/Q scan may offer less maternal 
radiation exposure and higher diagnostic accuracy compared to that of CTPA [3, 59, 60]. 
 
Impaired renal function 
Computed tomography pulmonary angiography is not a good option for the diagnosis of 
PE in patients with high risk for radio-contrast induced nephropathy. Magnetic resonance 
angiography carries a better renal safety profile and no radiation exposure [61]. However, 
gadolinium-related nephrogenic systemic fibrosis could occur [62]. V/Q scan is preferred 
over CTPA in patients with impaired renal function and suspicions of PE to avoid contrast 
mediated injury of the kidneys [63]. 
 
Conclusions  
Despite many advances in medical technology, there is still uncertainty about decisions in 
the diagnosis and prognosis of PE and treatment plans in clinical practice. A high index of 
clinical suspicion and selection and use of optimal CV imaging are essential in the diagnosis 
of PE. Physicians, therefore, should be familiar with the major advantages or pitfalls of 
various CV imaging modalities used in the evaluation of PE (Table 1). The optimal use of 
multimodality CV imaging enables the comprehensive assessment of anatomical and 
functional severity of PE and the prediction of prognosis as well as the decision for choosing 
therapeutic strategy. 
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Table 1. Comparisons of various cardiovascular imaging modalities in the assessment of 
pulmonary embolism (PE). 
Modality Advantages Disadvantages 
Transthoracic 
echocardiography 
(TTE) 
1. Bedside evaluation is possible 
2. Useful in the evaluation of 
treatment efficacy by serial exam 
3. Allows assessment of 
hemodynamics 
4. Relatively inexpensive cost 
5. Widely available equipment 
6. No radiation 
1. Operator-dependent 
2. Cannot identify the 
thrombus extent  
3. High sensitivity, low 
specificity   
4. Suboptimal in patients 
with poor imaging 
windows  
Computed tomography 
pulmonary 
angiography (CTPA) 
1. High diagnostic accuracy 
2. Diagnostic modality of choice 
3. Directly visualize the extent and 
burden of the thrombus 
4. Visualize thromboembolic 
resolution after treatment 
5. Allows assessment of other cardiac 
structures 
1. Radiation exposure 
2. Contrast 
administration precludes 
use in patients with 
advanced renal disease 
V/Q scan  1. High diagnostic accuracy 
2. Helps to distinguish CTEPH from 
acute PE 
1. Limited availability 
2. High cost 
3. Radiation exposure 
Magnetic resonance 
imaging (MRI) 
1. Free from ionizing radiation 
2. Can provide information on 
structure and flow mechanics 
1. Limited availability 
2. Gadolinium 
administration precludes 
use in patient with 
advanced renal disease 
3. High cost 
CTEPH — chronic thromboembolic pulmonary hypertension; V/Q — ventilation/perfusion 
 
 Table 2. Various scoring systems assessing pulmonary arterial clot load 
 
Pulmonary Artery Clot Load Scores 
Miller score [24, 28] 
n — number of obstructed arterial segments 
1 point for filling defects on any one of segmental branches 
Max.16 points: according to the involved lobal region 
— right: max. 9 points (upper 3, middle 2, lower 4) 
— left: max. 7 points (upper 2, middle 2, lower 3) 
Walsh score [27, 28] 
n — number of obstructed arterial segments 
1 point for segmental filling defect or obstruction 
Max. 18 points: according to the involved lobal region 
— max. 9 points for each lobe (upper 3, middle or lingular 2, lower 4) 
— max. 3 points for single central region 
Qanadli score [25] 
Qanadli index = ∑  (𝑛 ∗  𝑑)/40 *100 (CT obstruction index) 
n — number of obstructed arterial segments 
— 1: presence of embolus in a segmental artery 
d — degree of vascular obstruction 
— 0: no occlusion 
— 1: partial occlusion 
— 2: total occlusion 
— max. 40 points: 10 segmental arteries for each lobe 
Mastora score [26] 
n — number of obstructed arterial segments 
d — degree of vascular obstruction 
— 1: < 25% obstruction 
— 2: 25~49% obstruction 
— 3: 50~74% obstruction 
— 4: 75~99% obstruction 
— 5: 100% obstruction 
Scoring in each location level 
— central score (5 mediastinal and 6 lobar) 
— peripheral score (20 segmental) 
— global score (central and peripheral) 
Max. 155 points 
Max — maximal 
 
 
FIGURES LEGENDS 
 
Figure 2. Chest computed tomography angiography suggesting right ventricular (RV) 
dysfunction. RV dimension is greater than left ventricular dimension (A). Leftward 
ventricular septal bowing (B). Contrast reflux (arrows) to the inferior vena cava (C) and 
hepatic veins (D). 
 
Figure 3. Chest computed tomography angiography shows multifocal small filling defects in 
both pulmonary arteries (arrows) (A) and large filling defects resulting in near total occlusion 
of the left pulmonary artery (wide arrow) and filling defect in right pulmonary artery (narrow 
arrow) (B). 
 
Figure 4. Dual energy computed tomography (DECT) in a 55-year-old female with acute 
pulmonary embolism. Pre-treatment DECT shows multi-focal hypoperfused regions (dark-
brown color) corresponding to the location of vascular obstruction (A). Follow up DECT 
shows the disappearance of hypoperfused regions after 6-months of anticoagulation (B). 
 
Figure 5. Chest computed tomography angiography (CTPA) suggesting chronic 
thromboembolic pulmonary hypertension (CTEPH). Calcific thrombi (arrows) in right 
pulmonary artery on pre-enhance (A), post-enhance CTPA (B), eccentric (crescentic shape) 
thrombi (arrow heads; C, D), and nonuniform arterial perfusion pattern and mosaic pattern of 
lung attenuation (E, F).  
 
Figure 6. Ventilation/perfusion (V/Q) scans demonstrating pulmonary embolism. Moderate 
to large mismatch on V/Q scan: normal ventilation scan (A) and moderate-sized perfusion 
defect in right middle lung and large-sized perfusion defect in left upper lung on perfusion 
scan (B). A large-sized perfusion defect in right upper lung, and two, small-sized perfusion 
defects in left upper lung and a missed perfusion defect in anterior basal segment of right 
lower lung on perfusion planar image in perfusion single photon emission computed 
tomography-computed tomography (SPECT-CT; C); LPO — left posterior oblique; RPO — 
right posterior oblique. 
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